PCA
HUMA icon

Pallas Capital Advisors’s Humacyte HUMA Stock Holding History

Pallas Capital Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,600
Closed -$13.1K – 1066
2026
Q1 		$13.1K Buy
+21,600
New +$22.5K ﹤0.01% 859
2025
Q3 		– Sell
-19,877
Closed -$41.5K – 917
2025
Q2 		$41.5K Buy
+19,877
New +$38.2K ﹤0.01% 834

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pallas Capital Advisors's HUMA Position: Q2 2026 in Review

Pallas Capital Advisors sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 21,600 shares — an estimated $13.1K sold.

Pallas Capital Advisors first reported a position in HUMA in Q2 2025 and held it in 2 quarters. The position peaked at $41.5K in Q2 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Pallas Capital Advisors reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
  • Pallas Capital Advisors sold 21,600 Humacyte shares in Q2 2026, an estimated $13.1K.
  • Pallas Capital Advisors first reported a position in Humacyte in Q2 2025 and held it in 2 quarters.
  • Pallas Capital Advisors's Humacyte position peaked at $41.5K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.